Nathanson D, Ullman B, Lofstrom U, Hedman A, Frick M, Sjoholm A, Nystrom T: Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
Nauck reported, both doses of dulaglutide exceeded that standard and actually achieved statistically significant and clinically meaningful superiority to the dipeptidyl peptidase-4 inhibitor (see chart)
But Medicare, which is a federal insurance program for people 65 and older, does not cover these medications solely for weight management, only for diabetes and heart disease
See what the 10-year data suggests) While GLP-1 medications can have a number of potential side effects, it is important to note that these medications are generally considered safe and effective for the treatment of type 2 diabetes and for weight loss
This IPO will fuel progression across its pipeline, offering promising alternatives to injectable GLP-1 therapies
